Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 10:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,620 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pulmonary Disorder, Chronic Obstructive Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

NCT03162055
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease COPD
Interventions
Glycopyrronium/Formoterol Fumarate, umeclidinium/vilanterol
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 95 Years
Enrollment
1,119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
15
States / cities
Tempe, Arizona • Escondido, California • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced Sep 11, 2026, 10:25 PM EDT
Withdrawn Not applicable Interventional

The Impact of Interprofessional Training to Improve the Uptake of Noninvasive Ventilation in Patients Hospitalized With Severe COPD Exacerbation

NCT04206735
View directory record Official record
Conditions
Copd
Interventions
Interprofessional Education (IPE), Usual care
Other
Lead sponsor
Baystate Medical Center
Other
Eligibility
23 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 22, 2023 · Synced Sep 11, 2026, 10:25 PM EDT
Recruiting Phase 2 Interventional

Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy

NCT06660355
View directory record Official record
Conditions
Chronic Graft-versus-host Disease (cGVHD)
Interventions
Ruxolitinib, Prednisone
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
6
States / cities
Miami, Florida • Tampa, Florida • Kansas City, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 11, 2026, 10:25 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Lung Macrophage Populations and Functions in Chronic Obstructive Pulmonary Disease (COPD)-Susceptible Smokers

NCT04722835
View directory record Official record
Conditions
Copd, Smoking, Tobacco Use
Interventions
Bronchoscopy with Bronchoalveolar Lavage (BAL)
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2030
U.S. locations
3
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 11, 2026, 10:25 PM EDT
Terminated No phase listed Observational

Efficacy of High Flow Therapy in COPD At Home

NCT02230020
View directory record Official record
Conditions
COPD
Interventions
Nasal High Flow
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 7, 2017 · Synced Sep 11, 2026, 10:25 PM EDT
Completed Phase 4 Interventional Results available

Assessment In a Real World Setting of the Effect of Inhaled Steroid-based Triple Therapy Versus the Combination of Tiotropium and Olodaterol on Reducing Chronic Obstructive Pulmonary Disease (COPD) Exacerbations [AIRWISE]

NCT03265145
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Stiolto Respimat, ICS (Inhaled Corticosteroid) (Triple therapy), LABA (Long-Acting Beta Agonist) (Triple therapy), LAMA (Long-Acting Muscarinic Antagonist) (Triple therapy)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
714 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
90
States / cities
Mobile, Alabama • Montgomery, Alabama • Tucson, Arizona + 84 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2022 · Synced Sep 11, 2026, 10:25 PM EDT
Terminated Phase 3 Interventional Results available

Simvastatin Therapy for Moderate and Severe COPD

NCT01061671
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
simvastatin, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
40 Years to 80 Years
Enrollment
885 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
35
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2018 · Synced Sep 11, 2026, 10:25 PM EDT
Completed Phase 2 Interventional

Dose-Ranging Study of A006 DPI, in Adult Asthma Patients

NCT01174732
View directory record Official record
Conditions
Asthma, Bronchospasm
Interventions
albuterol inhalation powder, Placebo, albuterol inhalation aerosol
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
San Jose, California • Centennial, Colorado • Denver, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Sep 11, 2026, 10:25 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes

NCT02281084
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Oral Azacitidine, Durvalumab
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
23
States / cities
New Haven, Connecticut • Miami, Florida • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Sep 11, 2026, 10:25 PM EDT
Completed Phase 3 Interventional Results available

A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01879410
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
UMEC/VI Inhalation Powder 62.5/25 mcg via NDPI, FSC Inhalation Powder 250/50 mcg via ACCUHALER/DISKUS, Placebo DISKUS, Placebo NDPI
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
15
States / cities
Tucson, Arizona • Newport Beach, California • Riverside, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Sep 11, 2026, 10:25 PM EDT
Active, not recruiting Phase 2 Interventional

Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD)

NCT06940154
View directory record Official record
Conditions
COPD Acute Exacerbation
Interventions
Rademikibart in prefilled syringe, Matching placebo in prefilled syringe
Combination Product · Drug
Lead sponsor
Connect Biopharm LLC
Industry
Eligibility
40 Years to 80 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
21
States / cities
Birmingham, Alabama • Palo Alto, California • Valencia, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 11, 2026, 10:25 PM EDT
Terminated No phase listed Observational

Evaluating the Effects of Surgical and Non-Surgical Treatment Options in People With Emphysema

NCT00675454
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Emphysema
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
35 Years to 90 Years
Enrollment
802 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 1, 2021 · Synced Sep 11, 2026, 10:25 PM EDT
Terminated Phase 2 Interventional Results available

A Study Designed to Evaluate ODSH in Subjects With Exacerbations of COPD

NCT00457951
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Open-Label, Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride, ODSH
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
10
States / cities
Orange, California • Marietta, Georgia • Shreveport, Louisiana + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2021 · Synced Sep 11, 2026, 10:25 PM EDT
Completed Phase 4 Interventional Results available

Comparative Study of ELLIPTA Dry Powder Inhaler (DPI) Versus DISKUS DPI Used With HandiHaler DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT03227445
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
ELLIPTA placebo DPI, DISKUS placebo DPI, HandiHaler placebo DPI, Inhaler preference questionnaires
Device · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
18
States / cities
Orlando, Florida • Natchitoches, Louisiana • Saint Charles, Missouri + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Sep 11, 2026, 10:25 PM EDT
Completed Phase 2 Interventional Results available

PT003 MDI Cardiovascular Safety Study

NCT01349803
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
PT005 MDI, PT001 MDI, PT003 MDI, Formoterol Fumarate 12 μg (Foradil® Aerolizer®)
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
10
States / cities
Glendale, Arizona • Fullerton, California • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Sep 11, 2026, 10:25 PM EDT
Not listed Not applicable Interventional

Informatics Framework for Pulmonary Rehabilitation

NCT03981783
View directory record Official record
Conditions
COPD
Interventions
Best available care (BAC), Telerehabilitation (TH)
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 30, 2022 · Synced Sep 11, 2026, 10:25 PM EDT
Completed Phase 2 Interventional Results available

Sildenafil for Chronic Obstructive Pulmonary Disease

NCT00104637
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Emphysema
Interventions
sildenafil citrate, Placebo
Drug
Lead sponsor
Kawut, Steven, MD
Individual
Eligibility
40 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 20, 2012 · Synced Sep 11, 2026, 10:25 PM EDT
Completed Phase 3 Interventional Results available

The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency

NCT00301366
View directory record Official record
Conditions
Alpha 1-Antitrypsin Deficiency
Interventions
alpha-1 proteinase inhibitor (human)
Drug
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
8
States / cities
Denver, Colorado • Gainesville, Florida • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2014 · Synced Sep 11, 2026, 10:25 PM EDT
Terminated Not applicable Interventional Results available

Consequences of Nocturnal and Daytime Hypoxemia in COPD

NCT00547456
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Oxygen
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Dec 15, 2015 · Synced Sep 11, 2026, 10:25 PM EDT
Completed Phase 3 Interventional Results available

Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease

NCT01019694
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Combivent CFC-MDI, Combivent Respimat 20/100 mcg, Atrovent HFA 42 mcg + Albuterol HFA 200 mcg
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
55
States / cities
Jasper, Alabama • Mobile, Alabama • Mesa, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2014 · Synced Sep 11, 2026, 10:25 PM EDT
Completed Phase 3 Interventional Results available

An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A

NCT01328444
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
GSK 573719 +GW642444 125/25, GSK573719 + GW642444 62.5/25, GSK 573719 125, GSK 573719 62.5, GW642444 25, Plb
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
11
States / cities
Phoenix, Arizona • Lebanon, New Hampshire • Albany, New York + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2017 · Synced Sep 11, 2026, 10:25 PM EDT
Completed Not applicable Interventional

Device-guided Breathing for Shortness of Breath in COPD

NCT01286181
View directory record Official record
Conditions
COPD, Dyspnea, Hyperinflation
Interventions
Twice daily practice of device-guided slow breathing.
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 3, 2013 · Synced Sep 11, 2026, 10:25 PM EDT
Completed Phase 2 Interventional Results available

Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease

NCT01862536
View directory record Official record
Conditions
Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Tadalafil, placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years to 85 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
5
States / cities
West Los Angeles, California • Denver, Colorado • Decatur, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2021 · Synced Sep 11, 2026, 10:25 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

PatientSpot Formerly Known as ArthritisPower

NCT03840928
View directory record Official record
Conditions
Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout, Crohn Disease, Juvenile Idiopathic Arthritis, Lupus Erythematosus, Myositis, Osteoarthritis, Osteoporosis, Psoriasis, Psoriatic Arthritis, Scleroderma, Dermatomyositis, Inflammatory Bowel Diseases, Polymyositis, Axial Spondyloarthritis, Diffuse Idiopathic Skeletal Hyperostosis, Polymyalgia Rheumatica, Giant Cell Arteritis, Temporal Arteritis, Wegener, Relapsing Polychondritis, Undifferentiated Connective Tissue Disease, Spinal Cord Injuries, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Ataxia, Bell Palsy, Brain Tumor, Cerebral Aneurysm, Epilepsy, Guillain-Barre Syndrome, Headache, Head Injury, Hydrocephalus, Lumbar Disc Disease, Meningitis, Multiple Sclerosis, Muscular Dystrophy, Neurocutaneous Syndromes, Parkinson Disease, Stroke, Cluster Headache, Tension-Type Headache, Chronic Obstructive Pulmonary Disease, Asthma, Lung Cancer, Cystic Fibrosis, Sleep Apnea, Eczema, Alopecia, Chronic Inflammation, Unstable Angina, Heart Attack, Heart Failure, Arrythmia, Valve Heart Disease, High Blood Pressure, Congenital Heart Disease, Peripheral Arterial Disease, Diabetes, Chronic Liver Disease, Obesity
Interventions
Not listed
Lead sponsor
Global Healthy Living Foundation
Other
Eligibility
19 Years and older
Enrollment
40,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
Upper Nyack, New York
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Sep 11, 2026, 10:25 PM EDT